Hansoh Pharmaceutical (03692) Reports Interim Results with Shareholders' Profit of RMB 3.135 Billion, Up 15.02% Year-on-Year

Hansoh Pharma (03692) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of RMB 7.434 billion (in the same unit hereinafter), representing a year-on-year increase of 14.27%; profit attributable to owners of the parent company amounted to RMB 3.135 billion, increasing by 15.02% year-on-year; earnings per share were RMB 0.53, and an interim dividend of HKD 0.2316 per share is proposed.

The Company has seven innovative drugs produced in China that generate sales revenue, forming a rich product pipeline. For the six months ended June 30, 2025, the sales revenue of innovative drugs and cooperative products was approximately RMB 6.145 billion, accounting for about 82.7% of total revenue, which has become the core driving force for the sustainable growth of the Group's performance.

Our revenue mainly comes from the sales of pharmaceuticals. Our main products are concentrated in the key therapeutic areas that this Group strategically focuses on, including anti-tumor, anti-infection, central nervous system, metabolism, and other diseases. The increase in revenue, profit, and basic earnings per share during the reporting period was primarily due to the increase in sales revenue from innovative drugs and collaboration products.